{"version":"https://jsonfeed.org/version/1.1","title":"Rare Disease Venture Atlas — Live Myelofibrosis & Orphan Bio-Delta Wire","home_page_url":"https://rare-disease-atlas.github.io/","feed_url":"https://api.rare-disease-atlas.workers.dev/feeds/bio-delta.json","description":"Hourly edge-cached translational intelligence wire tracking 7 next-generation Myelofibrosis ClinicalTrials.gov v2 studies (JH2 allosteric, Type II JAK2, mutant CALR, telomerase OS), newest PubMed papers across JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / hepcidin, and paired Clonal PMF vs Reversible AIMF benchmarks.","language":"en-US","authors":[{"name":"Rare Disease Venture Atlas","url":"https://rare-disease-atlas.github.io/"}],"_atlas_meta":{"edge_cache_ttl_seconds":3600,"tracked_nct_ids":["NCT06313593","NCT06343805","NCT06034002","NCT04576156","NCT05210790","NCT06479135","NCT07362225"],"pubmed_query":"myelofibrosis AND (\"JAK2 V617F\" OR \"JH2\" OR \"autoimmune myelofibrosis\" OR \"hepcidin\")","live_trials_count":7,"live_pubmed_count":6,"atom_xml_url":"https://api.rare-disease-atlas.workers.dev/atom.xml","stress_test_oracle_url":"https://api.rare-disease-atlas.workers.dev/api/stress-test","mcp_endpoint":"https://api.rare-disease-atlas.workers.dev/mcp"},"items":[{"id":"urn:rare-disease-atlas:ctgov:NCT06343805:2026-11-12","url":"https://clinicaltrials.gov/study/NCT06343805","title":"[ClinicalTrials.gov NCT06343805 · RECRUITING] A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","content_text":"[RECRUITING · PHASE1 · Updated 2026-11-12] Sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Interventions: LY5830966. Primary Outcomes: Number of patients with treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).; Number of patients with Dose Limiting Toxicities (DLTs). Atlas Translational Note: Type II JAK2 inactive-conformation inhibitor — Designed to abolish Type I JAK2 activation-loop hyperphosphorylation persistence mediated by JAK1/TYK2 heterodimers.","summary":"[RECRUITING · PHASE1 · Updated 2026-11-12] Sponsor: Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company. Interventions: LY5830966. Primary Outcomes: Number of patients with treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).; Number of patients with Dose Limiting Toxicities (DLTs). Atlas Translational Note: Type II JAK2 inactive-conformation inhibitor — Designed to abolish Type I JAK2 activation-loop hyperphosphorylation persistence mediated by JAK1/TYK2 heterodimers.","date_modified":"2026-11-12T00:00:00Z","tags":["clinical-trial","myelofibrosis","NCT06343805","recruiting"],"_bio_delta":{"kind":"clinical_trial","nct_id":"NCT06343805","title":"A Phase 1 Study of LY5830966 in Participants With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","status":"RECRUITING","phases":["PHASE1"],"sponsor":"Ajax Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company","interventions":["LY5830966"],"primary_outcomes":["Number of patients with treatment-emergent adverse events (TEAEs) as assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v 5.0).","Number of patients with Dose Limiting Toxicities (DLTs)"],"last_updated":"2026-11-12","updated_iso":"2026-11-12T00:00:00Z","url":"https://clinicaltrials.gov/study/NCT06343805","atlas_agent":"AJ1-11095","atlas_axis":"Type II JAK2 inactive-conformation inhibitor","atlas_significance":"Designed to abolish Type I JAK2 activation-loop hyperphosphorylation persistence mediated by JAK1/TYK2 heterodimers."}},{"id":"urn:rare-disease-atlas:ctgov:NCT05210790:2026-10-19","url":"https://clinicaltrials.gov/study/NCT05210790","title":"[ClinicalTrials.gov NCT05210790 · ACTIVE_NOT_RECRUITING] A Study of Rusfertide in Adults With Polycythemia Vera (PV)","content_text":"[ACTIVE_NOT_RECRUITING · PHASE3 · Updated 2026-10-19] Sponsor: Protagonist Therapeutics, Inc.. Interventions: Rusfertide, Placebo. Primary Outcomes: Part 1a: Percentage of Participants Who Achieved Response. Atlas Translational Note: Hepcidin mimetic peptide for Polycythemia Vera erythrocytosis (Iron-Polarity Comparator) — Critical MPN polarity benchmark: restricts ferroportin iron export for PV cytoreduction, contrasting with ACVR1/IL-6 hepcidin suppression needed in anemic PMF/AIMF.","summary":"[ACTIVE_NOT_RECRUITING · PHASE3 · Updated 2026-10-19] Sponsor: Protagonist Therapeutics, Inc.. Interventions: Rusfertide, Placebo. Primary Outcomes: Part 1a: Percentage of Participants Who Achieved Response. Atlas Translational Note: Hepcidin mimetic peptide for Polycythemia Vera erythrocytosis (Iron-Polarity Comparator) — Critical MPN polarity benchmark: restricts ferroportin iron export for PV cytoreduction, contrasting with ACVR1/IL-6 hepcidin suppression needed in anemic PMF/AIMF.","date_modified":"2026-10-19T00:00:00Z","tags":["clinical-trial","myelofibrosis","NCT05210790","active_not_recruiting"],"_bio_delta":{"kind":"clinical_trial","nct_id":"NCT05210790","title":"A Study of Rusfertide in Adults With Polycythemia Vera (PV)","status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"sponsor":"Protagonist Therapeutics, Inc.","interventions":["Rusfertide","Placebo"],"primary_outcomes":["Part 1a: Percentage of Participants Who Achieved Response"],"last_updated":"2026-10-19","updated_iso":"2026-10-19T00:00:00Z","url":"https://clinicaltrials.gov/study/NCT05210790","atlas_agent":"Rusfertide (VERIFY Phase 3)","atlas_axis":"Hepcidin mimetic peptide for Polycythemia Vera erythrocytosis (Iron-Polarity Comparator)","atlas_significance":"Critical MPN polarity benchmark: restricts ferroportin iron export for PV cytoreduction, contrasting with ACVR1/IL-6 hepcidin suppression needed in anemic PMF/AIMF."}},{"id":"urn:rare-disease-atlas:ctgov:NCT06313593:2026-08-12","url":"https://clinicaltrials.gov/study/NCT06313593","title":"[ClinicalTrials.gov NCT06313593 · ACTIVE_NOT_RECRUITING] A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms","content_text":"[ACTIVE_NOT_RECRUITING · PHASE1 · Updated 2026-08-12] Sponsor: Incyte Corporation. Interventions: INCB160058, Standard disease-directed therapy. Primary Outcomes: Number of participants with Dose Limiting Toxicities (DLTs); Number of participants with Treatment-emergent Adverse Events (TEAEs). Atlas Translational Note: Mutant-selective JAK2 V617F JH2 pseudokinase allosteric inhibitor — Tests clonal VAF modification while sparing wild-type JAK2 JH1 EPO/TPO hematopoiesis (PDB:4FVQ vs 4FVP).","summary":"[ACTIVE_NOT_RECRUITING · PHASE1 · Updated 2026-08-12] Sponsor: Incyte Corporation. Interventions: INCB160058, Standard disease-directed therapy. Primary Outcomes: Number of participants with Dose Limiting Toxicities (DLTs); Number of participants with Treatment-emergent Adverse Events (TEAEs). Atlas Translational Note: Mutant-selective JAK2 V617F JH2 pseudokinase allosteric inhibitor — Tests clonal VAF modification while sparing wild-type JAK2 JH1 EPO/TPO hematopoiesis (PDB:4FVQ vs 4FVP).","date_modified":"2026-08-12T00:00:00Z","tags":["clinical-trial","myelofibrosis","NCT06313593","active_not_recruiting"],"_bio_delta":{"kind":"clinical_trial","nct_id":"NCT06313593","title":"A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms","status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"sponsor":"Incyte Corporation","interventions":["INCB160058","Standard disease-directed therapy"],"primary_outcomes":["Number of participants with Dose Limiting Toxicities (DLTs)","Number of participants with Treatment-emergent Adverse Events (TEAEs)"],"last_updated":"2026-08-12","updated_iso":"2026-08-12T00:00:00Z","url":"https://clinicaltrials.gov/study/NCT06313593","atlas_agent":"INCB160058","atlas_axis":"Mutant-selective JAK2 V617F JH2 pseudokinase allosteric inhibitor","atlas_significance":"Tests clonal VAF modification while sparing wild-type JAK2 JH1 EPO/TPO hematopoiesis (PDB:4FVQ vs 4FVP)."}},{"id":"urn:rare-disease-atlas:ctgov:NCT04576156:2026-07-08","url":"https://clinicaltrials.gov/study/NCT04576156","title":"[ClinicalTrials.gov NCT04576156 · ACTIVE_NOT_RECRUITING] A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","content_text":"[ACTIVE_NOT_RECRUITING · PHASE3 · Updated 2026-07-08] Sponsor: Geron Corporation. Interventions: Imetelstat, Best Available Therapy (BAT). Primary Outcomes: Overall survival (OS). Atlas Translational Note: First-in-class telomerase inhibitor (Phase 3 Overall Survival primary endpoint) — Gold-standard post-JAK-inhibitor R/R MF regulatory benchmark using Overall Survival rather than SVR35 alone.","summary":"[ACTIVE_NOT_RECRUITING · PHASE3 · Updated 2026-07-08] Sponsor: Geron Corporation. Interventions: Imetelstat, Best Available Therapy (BAT). Primary Outcomes: Overall survival (OS). Atlas Translational Note: First-in-class telomerase inhibitor (Phase 3 Overall Survival primary endpoint) — Gold-standard post-JAK-inhibitor R/R MF regulatory benchmark using Overall Survival rather than SVR35 alone.","date_modified":"2026-07-08T00:00:00Z","tags":["clinical-trial","myelofibrosis","NCT04576156","active_not_recruiting"],"_bio_delta":{"kind":"clinical_trial","nct_id":"NCT04576156","title":"A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment","status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"sponsor":"Geron Corporation","interventions":["Imetelstat","Best Available Therapy (BAT)"],"primary_outcomes":["Overall survival (OS)"],"last_updated":"2026-07-08","updated_iso":"2026-07-08T00:00:00Z","url":"https://clinicaltrials.gov/study/NCT04576156","atlas_agent":"Imetelstat (IMpactMF)","atlas_axis":"First-in-class telomerase inhibitor (Phase 3 Overall Survival primary endpoint)","atlas_significance":"Gold-standard post-JAK-inhibitor R/R MF regulatory benchmark using Overall Survival rather than SVR35 alone."}},{"id":"urn:rare-disease-atlas:ctgov:NCT06034002:2026-04-17","url":"https://clinicaltrials.gov/study/NCT06034002","title":"[ClinicalTrials.gov NCT06034002 · RECRUITING] A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","content_text":"[RECRUITING · PHASE1 · Updated 2026-04-17] Sponsor: Incyte Corporation. Interventions: INCA033989, Ruxolitinib. Primary Outcomes: Number of participants with Dose Limiting Toxicities (DLTs); Number of participants with Treatment-emergent Adverse Events (TEAEs). Atlas Translational Note: Mutant CALR cell-surface neoepitope monoclonal antibody — Validates selective clonal eradication in CALR-mutant myelofibrosis and essential thrombocythemia.","summary":"[RECRUITING · PHASE1 · Updated 2026-04-17] Sponsor: Incyte Corporation. Interventions: INCA033989, Ruxolitinib. Primary Outcomes: Number of participants with Dose Limiting Toxicities (DLTs); Number of participants with Treatment-emergent Adverse Events (TEAEs). Atlas Translational Note: Mutant CALR cell-surface neoepitope monoclonal antibody — Validates selective clonal eradication in CALR-mutant myelofibrosis and essential thrombocythemia.","date_modified":"2026-04-17T00:00:00Z","tags":["clinical-trial","myelofibrosis","NCT06034002","recruiting"],"_bio_delta":{"kind":"clinical_trial","nct_id":"NCT06034002","title":"A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms","status":"RECRUITING","phases":["PHASE1"],"sponsor":"Incyte Corporation","interventions":["INCA033989","Ruxolitinib"],"primary_outcomes":["Number of participants with Dose Limiting Toxicities (DLTs)","Number of participants with Treatment-emergent Adverse Events (TEAEs)"],"last_updated":"2026-04-17","updated_iso":"2026-04-17T00:00:00Z","url":"https://clinicaltrials.gov/study/NCT06034002","atlas_agent":"INCA033989","atlas_axis":"Mutant CALR cell-surface neoepitope monoclonal antibody","atlas_significance":"Validates selective clonal eradication in CALR-mutant myelofibrosis and essential thrombocythemia."}},{"id":"urn:rare-disease-atlas:ctgov:NCT07362225:2026-01-23","url":"https://clinicaltrials.gov/study/NCT07362225","title":"[ClinicalTrials.gov NCT07362225 · RECRUITING] MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","content_text":"[RECRUITING · Clinical · Updated 2026-01-23] Sponsor: MPN Research Foundation. Interventions: MPN PROGRESSion Longitudinal Registry. Primary Outcomes: Time to Disease Progression. Atlas Translational Note: Prospective natural-history & clonal evolution MPN progression cohort — Real-world biomarker and progression registry benchmark informing MPN-to-MF risk stratification.","summary":"[RECRUITING · Clinical · Updated 2026-01-23] Sponsor: MPN Research Foundation. Interventions: MPN PROGRESSion Longitudinal Registry. Primary Outcomes: Time to Disease Progression. Atlas Translational Note: Prospective natural-history & clonal evolution MPN progression cohort — Real-world biomarker and progression registry benchmark informing MPN-to-MF risk stratification.","date_modified":"2026-01-23T00:00:00Z","tags":["clinical-trial","myelofibrosis","NCT07362225","recruiting"],"_bio_delta":{"kind":"clinical_trial","nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","status":"RECRUITING","phases":[],"sponsor":"MPN Research Foundation","interventions":[],"primary_outcomes":["Time to Disease Progression"],"last_updated":"2026-01-23","updated_iso":"2026-01-23T00:00:00Z","url":"https://clinicaltrials.gov/study/NCT07362225","atlas_agent":"MPN PROGRESSion Longitudinal Registry","atlas_axis":"Prospective natural-history & clonal evolution MPN progression cohort","atlas_significance":"Real-world biomarker and progression registry benchmark informing MPN-to-MF risk stratification."}},{"id":"urn:rare-disease-atlas:ctgov:NCT06479135:2025-09-25","url":"https://clinicaltrials.gov/study/NCT06479135","title":"[ClinicalTrials.gov NCT06479135 · RECRUITING] Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","content_text":"[RECRUITING · PHASE3 · Updated 2025-09-25] Sponsor: Kartos Therapeutics, Inc.. Interventions: Navtemadlin, Navtemadlin placebo, Ruxolitinib. Primary Outcomes: To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2; To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2. Atlas Translational Note: MDM2 inhibitor restoring wild-type TP53 apoptosis in suboptimal ruxolitinib MF responders — Phase 3 add-on benchmark testing clonal CD34+ depletion in TP53-wild-type myelofibrosis.","summary":"[RECRUITING · PHASE3 · Updated 2025-09-25] Sponsor: Kartos Therapeutics, Inc.. Interventions: Navtemadlin, Navtemadlin placebo, Ruxolitinib. Primary Outcomes: To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2; To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2. Atlas Translational Note: MDM2 inhibitor restoring wild-type TP53 apoptosis in suboptimal ruxolitinib MF responders — Phase 3 add-on benchmark testing clonal CD34+ depletion in TP53-wild-type myelofibrosis.","date_modified":"2025-09-25T00:00:00Z","tags":["clinical-trial","myelofibrosis","NCT06479135","recruiting"],"_bio_delta":{"kind":"clinical_trial","nct_id":"NCT06479135","title":"Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib","status":"RECRUITING","phases":["PHASE3"],"sponsor":"Kartos Therapeutics, Inc.","interventions":["Navtemadlin","Navtemadlin placebo","Ruxolitinib"],"primary_outcomes":["To compare spleen volume reduction (SVR35) between Arm 1 and Arm 2","To compare total symptom score reduction (TSS50) between Arm 1 and Arm 2"],"last_updated":"2025-09-25","updated_iso":"2025-09-25T00:00:00Z","url":"https://clinicaltrials.gov/study/NCT06479135","atlas_agent":"Navtemadlin + Ruxolitinib (POIESIS)","atlas_axis":"MDM2 inhibitor restoring wild-type TP53 apoptosis in suboptimal ruxolitinib MF responders","atlas_significance":"Phase 3 add-on benchmark testing clonal CD34+ depletion in TP53-wild-type myelofibrosis."}},{"id":"urn:rare-disease-atlas:pubmed:43006061","url":"https://pubmed.ncbi.nlm.nih.gov/43006061/","title":"[PubMed PMID:43006061] Laparoscopic splenectomy for a 30-cm supermassive spleen complicated by delayed hemorrhage: a case report","content_text":"[PubMed PMID:43006061 · International journal of surgery case reports · 2026 Nov] Authors: Surakitbowon D, Wattanasuttivong S, Yingruxpund T. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","summary":"[PubMed PMID:43006061 · International journal of surgery case reports · 2026 Nov] Authors: Surakitbowon D, Wattanasuttivong S, Yingruxpund T. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","date_modified":"2026-09-22T00:00:00Z","tags":["pubmed","myelofibrosis","PMID:43006061"],"_bio_delta":{"kind":"pubmed_paper","pmid":"43006061","title":"Laparoscopic splenectomy for a 30-cm supermassive spleen complicated by delayed hemorrhage: a case report","journal":"International journal of surgery case reports","pubdate":"2026 Nov","sortpubdate":"2026/09/22 00:00","authors":"Surakitbowon D, Wattanasuttivong S, Yingruxpund T","url":"https://pubmed.ncbi.nlm.nih.gov/43006061/"}},{"id":"urn:rare-disease-atlas:pubmed:42980647","url":"https://pubmed.ncbi.nlm.nih.gov/42980647/","title":"[PubMed PMID:42980647] Momelotinib for the treatment of myelofibrosis in patients with moderate-to-severe anemia: a drug safety evaluation","content_text":"[PubMed PMID:42980647 · Expert opinion on drug safety · 2026 Nov 4] Authors: Duminuco A, Harrington P. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","summary":"[PubMed PMID:42980647 · Expert opinion on drug safety · 2026 Nov 4] Authors: Duminuco A, Harrington P. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","date_modified":"2026-11-04T00:00:00Z","tags":["pubmed","myelofibrosis","PMID:42980647"],"_bio_delta":{"kind":"pubmed_paper","pmid":"42980647","title":"Momelotinib for the treatment of myelofibrosis in patients with moderate-to-severe anemia: a drug safety evaluation","journal":"Expert opinion on drug safety","pubdate":"2026 Nov 4","sortpubdate":"2026/11/04 00:00","authors":"Duminuco A, Harrington P","url":"https://pubmed.ncbi.nlm.nih.gov/42980647/"}},{"id":"urn:rare-disease-atlas:pubmed:42938929","url":"https://pubmed.ncbi.nlm.nih.gov/42938929/","title":"[PubMed PMID:42938929] Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms","content_text":"[PubMed PMID:42938929 · Cancers · 2026 Oct 20] Authors: Markey GE, Langabeer SE. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","summary":"[PubMed PMID:42938929 · Cancers · 2026 Oct 20] Authors: Markey GE, Langabeer SE. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","date_modified":"2026-10-20T00:00:00Z","tags":["pubmed","myelofibrosis","PMID:42938929"],"_bio_delta":{"kind":"pubmed_paper","pmid":"42938929","title":"Measurable Residual Disease (MRD) Monitoring in Myeloproliferative Neoplasms","journal":"Cancers","pubdate":"2026 Oct 20","sortpubdate":"2026/10/20 00:00","authors":"Markey GE, Langabeer SE","url":"https://pubmed.ncbi.nlm.nih.gov/42938929/"}},{"id":"urn:rare-disease-atlas:pubmed:42897234","url":"https://pubmed.ncbi.nlm.nih.gov/42897234/","title":"[PubMed PMID:42897234] Predicting long-term survival in primary myelofibrosis","content_text":"[PubMed PMID:42897234 · Leukemia · 2026 Oct 19] Authors: Barosi G, Rosti V, De Silvestri A. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","summary":"[PubMed PMID:42897234 · Leukemia · 2026 Oct 19] Authors: Barosi G, Rosti V, De Silvestri A. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","date_modified":"2026-10-19T00:00:00Z","tags":["pubmed","myelofibrosis","PMID:42897234"],"_bio_delta":{"kind":"pubmed_paper","pmid":"42897234","title":"Predicting long-term survival in primary myelofibrosis","journal":"Leukemia","pubdate":"2026 Oct 19","sortpubdate":"2026/10/19 00:00","authors":"Barosi G, Rosti V, De Silvestri A","url":"https://pubmed.ncbi.nlm.nih.gov/42897234/"}},{"id":"urn:rare-disease-atlas:pubmed:42890906","url":"https://pubmed.ncbi.nlm.nih.gov/42890906/","title":"[PubMed PMID:42890906] Biopsy-Proven Hepatic Extramedullary Hematopoiesis With Chronic Portal Vein Thrombosis in JAK2 V617F-Positive Prefibrotic Myelofibrosis: Contributors to Noncirrhotic Portal Hypertension","content_text":"[PubMed PMID:42890906 · ACG case reports journal · 2026 Oct] Authors: Bandaranaike R, Rutland B, Rutland T. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","summary":"[PubMed PMID:42890906 · ACG case reports journal · 2026 Oct] Authors: Bandaranaike R, Rutland B, Rutland T. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","date_modified":"2026-10-16T00:00:00Z","tags":["pubmed","myelofibrosis","PMID:42890906"],"_bio_delta":{"kind":"pubmed_paper","pmid":"42890906","title":"Biopsy-Proven Hepatic Extramedullary Hematopoiesis With Chronic Portal Vein Thrombosis in JAK2 V617F-Positive Prefibrotic Myelofibrosis: Contributors to Noncirrhotic Portal Hypertension","journal":"ACG case reports journal","pubdate":"2026 Oct","sortpubdate":"2026/10/16 00:00","authors":"Bandaranaike R, Rutland B, Rutland T","url":"https://pubmed.ncbi.nlm.nih.gov/42890906/"}},{"id":"urn:rare-disease-atlas:pubmed:42868322","url":"https://pubmed.ncbi.nlm.nih.gov/42868322/","title":"[PubMed PMID:42868322] VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy","content_text":"[PubMed PMID:42868322 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 Oct 13] Authors: Kuykendall AT, Bankar A, Pettit KM. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","summary":"[PubMed PMID:42868322 · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 Oct 13] Authors: Kuykendall AT, Bankar A, Pettit KM. Indexed under Myelofibrosis / JAK2 V617F / JH2 / Autoimmune Myelofibrosis (AIMF) / Hepcidin surveillance.","date_modified":"2026-10-13T00:00:00Z","tags":["pubmed","myelofibrosis","PMID:42868322"],"_bio_delta":{"kind":"pubmed_paper","pmid":"42868322","title":"VERIFY: A Phase III Trial of Rusfertide Versus Placebo in Phlebotomy-Dependent Patients With Polycythemia Vera Receiving Standard-of-Care Therapy","journal":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology","pubdate":"2026 Oct 13","sortpubdate":"2026/10/13 00:00","authors":"Kuykendall AT, Bankar A, Pettit KM","url":"https://pubmed.ncbi.nlm.nih.gov/42868322/"}},{"id":"urn:rare-disease-atlas:anchor:jak2-vs-aimf-v1.6","url":"https://rare-disease-atlas.github.io/","title":"Atlas Flagship Translational Anchor: Clonal JAK2 V617F+ PMF vs. Reversible JAK2-Negative Autoimmune Myelofibrosis (AIMF)","content_text":"Paired Flagship Reference: (1) Clonal JAK2 V617F+ Primary Myelofibrosis (ORPHA:824) — mutant JH2 pseudokinase allosteric selectivity (PDB:4FVQ, INCB160058 NCT06313593) and Type II persistence breaking (AJ1-11095 NCT06343805) vs pan-JAK1/2 JH1 cytopenic failure modes; (2) Reversible JAK2-Negative Autoimmune Myelofibrosis (AIMF) — 'Nature's Positive Control' demonstrating 74-80% human marrow fibrosis reversal (MF-2/3 -> MF-0/1) on immunomodulation plus dual transfusional + IL-6/STAT3/hepcidin/ferroportin iron overload triage. Stress-test any orphan hypothesis free at https://api.rare-disease-atlas.workers.dev/api/stress-test","summary":"Paired Flagship Reference: (1) Clonal JAK2 V617F+ Primary Myelofibrosis (ORPHA:824) — mutant JH2 pseudokinase allosteric selectivity (PDB:4FVQ, INCB160058 NCT06313593) and Type II persistence breaking (AJ1-11095 NCT06343805) vs pan-JAK1/2 JH1 cytopenic failure modes; (2) Reversible JAK2-Negative Autoimmune Myelofibrosis (AIMF) — 'Nature's Positive Control' demonstrating 74-80% human marrow fibrosis reversal (MF-2/3 -> MF-0/1) on immunomodulation plus dual transfusional + IL-6/STAT3/hepcidin/ferroportin iron overload triage. Stress-test any orphan hypothesis free at https://api.rare-disease-atlas.workers.dev/api/stress-test","date_modified":"2026-11-12T00:00:00Z","tags":["flagship-anchor","jak2-myelofibrosis","autoimmune-myelofibrosis","hepcidin","JH2"],"_bio_delta":{"kind":"flagship_anchor","flagship_ids":["jak2-myelofibrosis","autoimmune-myelofibrosis"],"stress_test_oracle":"https://api.rare-disease-atlas.workers.dev/api/stress-test"}}]}